A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma

NCT01030783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

517

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: tivozanib (AV-951)
DRUG: Sorafenib

Sponsor

AVEO Pharmaceuticals, Inc.